Dr Ravi on the Use of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

Praful K. Ravi, MB, BChir, MRCP, discusses the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer, highlighting the use of the targeted radioligand lutetium Lu 177 vipivotide tetraxetan.

Related Keywords

,Prafulk Ravi ,Harvard Medical School ,Dana Farber Cancer Institute ,Lank Center ,Genitourinary Oncology ,Science Summit ,Onclive Tv ,Precision Medicine In Oncology ,